Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$0.16 - $0.22 $3,914 - $5,381
24,463 New
24,463 $4,000
Q3 2022

Nov 10, 2022

SELL
$0.6 - $12.6 $1,584 - $33,276
-2,641 Reduced 81.31%
607 $0
Q2 2022

Aug 10, 2022

BUY
$0.95 - $1.22 $3,085 - $3,962
3,248 New
3,248 $3,000
Q4 2021

Feb 14, 2022

SELL
$1.38 - $1.74 $1,618 - $2,041
-1,173 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$1.59 - $1.87 $1,865 - $2,193
1,173 New
1,173 $2,000
Q1 2021

May 12, 2021

SELL
$1.81 - $3.88 $2,523 - $5,408
-1,394 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$1.5 - $2.02 $2,091 - $2,815
1,394 New
1,394 $3,000
Q3 2020

Nov 12, 2020

SELL
$1.58 - $2.37 $796 - $1,194
-504 Closed
0 $0
Q2 2020

Jul 31, 2020

SELL
$1.16 - $2.61 $5,927 - $13,337
-5,110 Reduced 91.02%
504 $1,000
Q1 2020

May 01, 2020

BUY
$1.06 - $2.16 $5,950 - $12,126
5,614 New
5,614 $8,000
Q4 2019

Feb 14, 2020

SELL
$1.69 - $2.16 $4,192 - $5,358
-2,481 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$1.69 - $2.92 $4,192 - $7,244
2,481 New
2,481 $4,000
Q2 2019

Aug 14, 2019

SELL
$1.89 - $4.01 $2,360 - $5,008
-1,249 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$1.66 - $5.9 $17,503 - $62,209
-10,544 Reduced 89.41%
1,249 $4,000
Q4 2018

Feb 14, 2019

BUY
$1.57 - $2.49 $18,515 - $29,364
11,793 New
11,793 $19,000
Q3 2018

Nov 14, 2018

SELL
$1.82 - $2.56 $5,114 - $7,193
-2,810 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$1.77 - $2.28 $4,973 - $6,406
2,810 New
2,810 $5,000
Q1 2018

May 15, 2018

SELL
$1.77 - $4.39 $175 - $434
-99 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$4.08 - $7.4 $8,457 - $15,340
-2,073 Reduced 95.44%
99 $0
Q3 2017

Nov 14, 2017

SELL
$3.42 - $8.74 $1,918 - $4,903
-561 Reduced 20.53%
2,172 $13,000
Q2 2017

Aug 14, 2017

SELL
N/A
-1,804 Reduced 39.76%
2,733 $13,000
Q1 2017

Nov 14, 2017

BUY
N/A
4,537
4,537 $50,000

About Akari Therapeutics Plc


  • Ticker AKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,349,200
  • Market Cap $164M
  • Description
  • Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...
More about AKTX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.